(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Clinical trial NCT04910685 · RECRUITING
Trial details
- NCT number
- NCT04910685
- Sponsor
- Blueprint Medicines Corporation
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-30
- Primary completion
- 2032-09-30
- Enrollment
- 534
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.